Display options
Cite
Brinkman CC, Peske JD, Engelhard VH. Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol. 2013;4:241doi: 10.3389/fimmu.2013.00241.
Brinkman, C. C., Peske, J. D., & Engelhard, V. H. (2013). Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Frontiers in immunology, 4241. https://doi.org/10.3389/fimmu.2013.00241
Brinkman, C Colin, et al. "Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues." Frontiers in immunology vol. 4 (2013): 241. doi: https://doi.org/10.3389/fimmu.2013.00241
Brinkman CC, Peske JD, Engelhard VH. Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues. Front Immunol. 2013 Aug 19;4:241. doi: 10.3389/fimmu.2013.00241. eCollection 2013. PMID: 23966998; PMCID: PMC3746678.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2013 Aug 19;4:241. doi: 10.3389/fimmu.2013.00241. eCollection 2013.

Peripheral tissue homing receptor control of naïve, effector, and memory CD8 T cell localization in lymphoid and non-lymphoid tissues.

Frontiers in immunology

C Colin Brinkman, J David Peske, Victor Henry Engelhard

Affiliations

  1. Department of Microbiology, Immunology, and Cancer Biology, Carter Immunology Center, University of Virginia School of Medicine , Charlottesville, VA , USA.

PMID: 23966998 PMCID: PMC3746678 DOI: 10.3389/fimmu.2013.00241

Abstract

T cell activation induces homing receptors that bind ligands on peripheral tissue vasculature, programing movement to sites of infection and injury. There are three major types of CD8 effector T cells based on homing receptor expression, which arise in distinct lymphoid organs. Recent publications indicate that naïve, effector, and memory T cell migration is more complex than once thought; while many effectors enter peripheral tissues, some re-enter lymph nodes (LN), and contain central memory precursors. LN re-entry can depend on CD62L or peripheral tissue homing receptors. Memory T cells in LN tend to express the same homing receptors as their forebears, but often are CD62Lneg. Homing receptors also control CD8 T cell tumor entry. Tumor vasculature has low levels of many peripheral tissue homing receptor ligands, but portions of it resemble high endothelial venules (HEV), enabling naïve T cell entry, activation, and subsequent effector activity. This vasculature is associated with positive prognoses in humans, suggesting it may sustain ongoing anti-tumor responses. These findings reveal new roles for homing receptors expressed by naïve, effector, and memory CD8 T cells in controlling entry into lymphoid and non-lymphoid tissues.

Keywords: T cell heterogeneity; T cell memory; T cell migration; T cell recirculation; T cell trafficking; effector T cell migration; memory T cell trafficking; tumor infiltrating lymphocytes

References

  1. Eur J Immunol. 1998 Nov;28(11):3832-9 - PubMed
  2. J Immunol. 1996 May 15;156(10):3727-36 - PubMed
  3. Immunity. 2006 Sep;25(3):511-20 - PubMed
  4. J Immunol. 2007 Jun 15;178(12):8073-80 - PubMed
  5. Science. 2001 Mar 23;291(5512):2413-7 - PubMed
  6. J Clin Invest. 2011 Oct;121(10):3846-59 - PubMed
  7. J Immunol. 2004 Apr 15;172(8):4875-82 - PubMed
  8. Cancers (Basel). 2011 Dec 28;4(1):1-10 - PubMed
  9. J Immunol. 2001 Oct 15;167(8):4476-84 - PubMed
  10. J Exp Med. 2003 Sep 15;198(6):963-9 - PubMed
  11. Immunol Rev. 2007 Feb;215:226-42 - PubMed
  12. Nat Immunol. 2005 Sep;6(9):889-94 - PubMed
  13. J Clin Invest. 1996 Jan 15;97(2):515-21 - PubMed
  14. Eur J Immunol. 2011 May;41(5):1192-5 - PubMed
  15. J Biol Chem. 1995 Sep 15;270(37):21966-74 - PubMed
  16. Science. 2006 Sep 29;313(5795):1960-4 - PubMed
  17. J Immunol. 2010 Apr 15;184(8):4079-86 - PubMed
  18. Nature. 1999 Oct 14;401(6754):708-12 - PubMed
  19. J Natl Cancer Inst. 1989 Nov 15;81(22):1709-17 - PubMed
  20. J Exp Med. 2008 Sep 29;205(10):2221-34 - PubMed
  21. J Immunol. 2013 Sep 1;191(5):2412-25 - PubMed
  22. J Immunother. 2005 Jul-Aug;28(4):343-51 - PubMed
  23. J Virol. 2005 Apr;79(7):4510-3 - PubMed
  24. Nat Immunol. 2007 Jul;8(7):743-52 - PubMed
  25. J Exp Med. 2008 Oct 27;205(11):2561-74 - PubMed
  26. J Immunol. 1999 May 15;162(10):5965-72 - PubMed
  27. J Immunol. 1994 Apr 1;152(7):3282-93 - PubMed
  28. J Immunol. 2013 Feb 1;190(3):970-6 - PubMed
  29. J Immunol. 2005 Apr 1;174(7):3959-66 - PubMed
  30. Arthritis Res Ther. 2009;11(1):R24 - PubMed
  31. Science. 2010 Feb 26;327(5969):1098-102 - PubMed
  32. J Immunol. 2004 Jan 15;172(2):857-63 - PubMed
  33. J Immunol. 2001 Jan 15;166(2):877-84 - PubMed
  34. Annu Rev Immunol. 2004;22:129-56 - PubMed
  35. Immunity. 2004 Oct;21(4):527-38 - PubMed
  36. J Exp Med. 2010 Mar 15;207(3):553-64 - PubMed
  37. J Immunother. 2010 Nov-Dec;33(9):965-74 - PubMed
  38. J Exp Med. 2002 Jan 7;195(1):135-41 - PubMed
  39. Nat Immunol. 2004 Feb;5(2):141-9 - PubMed
  40. Cancer Res. 2012 Mar 1;72(5):1070-80 - PubMed
  41. J Clin Oncol. 1989 Feb;7(2):250-61 - PubMed
  42. Nat Immunol. 2009 Aug;10(8):857-63 - PubMed
  43. Eur J Immunol. 2005 Apr;35(4):1056-65 - PubMed
  44. J Immunol. 1997 Aug 15;159(4):1746-52 - PubMed
  45. Respir Res. 2009 Oct 22;10:97 - PubMed
  46. Nat Immunol. 2005 Sep;6(9):895-901 - PubMed
  47. J Exp Med. 1996 Apr 1;183(4):1461-72 - PubMed
  48. Eur J Pharmacol. 2009 Jan 28;603(1-3):138-46 - PubMed
  49. J Immunol. 2005 Mar 15;174(6):3416-20 - PubMed
  50. Clin Cancer Res. 2007 May 1;13(9):2549-56 - PubMed
  51. Eur J Immunol. 2002 Jun;32(6):1792-801 - PubMed
  52. J Clin Invest. 2011 Jun;121(6):2371-82 - PubMed
  53. J Immunol. 2006 Apr 1;176(7):4431-9 - PubMed
  54. J Immunol. 2001 Feb 1;166(3):1813-22 - PubMed
  55. J Pathol. 1999 Dec;189(4):552-8 - PubMed
  56. J Immunol. 2007 Feb 1;178(3):1512-22 - PubMed
  57. Annu Rev Immunol. 2011;29:235-71 - PubMed
  58. J Exp Med. 2003 May 5;197(9):1153-63 - PubMed
  59. Clin Cancer Res. 2002 Dec;8(12):3803-12 - PubMed
  60. J Immunol. 2010 Feb 15;184(4):1909-17 - PubMed
  61. Nature. 2003 Jul 3;424(6944):88-93 - PubMed
  62. J Immunol. 2007 Mar 15;178(6):3358-62 - PubMed
  63. Int Immunol. 2009 Apr;21(4):361-77 - PubMed
  64. Cancer Res. 2003 May 1;63(9):2322-9 - PubMed
  65. Nat Med. 2008 Jan;14(1):28-36 - PubMed
  66. Immunity. 2005 Feb;22(2):175-84 - PubMed
  67. Nat Rev Cancer. 2012 Mar 15;12(4):298-306 - PubMed
  68. Clin Cancer Res. 2001 Feb;7(2):285-9 - PubMed
  69. Int J Cancer. 2005 Oct 10;116(6):949-56 - PubMed
  70. Microcirculation. 1998;5(2-3):153-71 - PubMed
  71. J Immunol. 2012 Jun 15;188(12):5811-7 - PubMed
  72. J Exp Med. 2000 Sep 4;192(5):761-8 - PubMed
  73. Nat Rev Immunol. 2007 Sep;7(9):678-89 - PubMed
  74. Cell. 1995 Feb 10;80(3):413-22 - PubMed
  75. Eur J Immunol. 2001 Aug;31(8):2411-20 - PubMed
  76. Immunity. 2004 May;20(5):551-62 - PubMed
  77. Sci Rep. 2012;2:765 - PubMed
  78. Trends Immunol. 2006 May;27(5):235-43 - PubMed
  79. Eur J Immunol. 2006 Feb;36(2):457-67 - PubMed
  80. Nat Immunol. 2006 Apr;7(4):344-53 - PubMed
  81. Immunity. 2005 Nov;23(5):539-50 - PubMed
  82. J Exp Med. 2001 Nov 19;194(10):1541-7 - PubMed
  83. J Clin Invest. 2000 Mar;105(5):683-91 - PubMed
  84. J Exp Med. 2004 Sep 20;200(6):725-35 - PubMed
  85. Am J Physiol Regul Integr Comp Physiol. 2002 Jul;283(1):R7-28 - PubMed
  86. J Exp Med. 2009 Jan 16;206(1):233-48 - PubMed
  87. Nat Immunol. 2003 Mar;4(3):225-34 - PubMed
  88. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15 - PubMed
  89. J Immunol. 2008 Sep 1;181(5):3099-107 - PubMed
  90. J Exp Med. 2005 Jan 17;201(2):303-16 - PubMed
  91. Nat Immunol. 2005 Aug;6(8):793-9 - PubMed
  92. J Immunol. 2008 Aug 1;181(3):1814-24 - PubMed
  93. Am J Pathol. 2011 Jul;179(1):37-45 - PubMed
  94. J Exp Med. 2010 Aug 2;207(8):1791-804 - PubMed
  95. J Exp Med. 2003 Oct 6;198(7):1023-34 - PubMed
  96. Blood. 2006 May 1;107(9):3447-54 - PubMed
  97. Nat Immunol. 2007 Mar;8(3):285-93 - PubMed
  98. J Exp Med. 1991 Dec 1;174(6):1461-6 - PubMed
  99. Science. 1996 Apr 5;272(5258):60-6 - PubMed
  100. Nature. 2011 Aug 14;477(7363):216-9 - PubMed
  101. J Immunol. 2002 Oct 15;169(8):4307-13 - PubMed
  102. J Exp Med. 2003 May 19;197(10):1255-67 - PubMed
  103. Cancer Res. 2011 Sep 1;71(17):5678-87 - PubMed
  104. J Immunol. 2002 Mar 1;168(5):2139-46 - PubMed
  105. FASEB J. 2012 Jan;26(1):51-62 - PubMed
  106. Nat Rev Immunol. 2012 Nov;12(11):762-73 - PubMed

Publication Types

Grant support